Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
In patients with IPF, inhaled treprostinil was associated with a smaller decline in FVC and fewer clinical-worsening events than placebo over a period of 52 weeks. (Funded by United Therapeutics; TETON-2 ClinicalTrials.gov number, NCT05255991.).
Authors
- C. Q. Deng (ORCID: https://orcid.org/0000-0002-5641-4101)
- John A. Mackintosh (ORCID: https://orcid.org/0000-0002-5254-4144)
- Natalie Breytenbach (ORCID: https://orcid.org/0000-0002-0545-6432)
- S. Nathan
- K Flaherty
- Wim Wuyts (ORCID: https://orcid.org/0000-0001-9648-3497)
- Christopher King (ORCID: https://orcid.org/0000-0002-2127-0902)
- Leigh Peterson (ORCID: https://orcid.org/0009-0007-1218-5435)
- J M Song
- Daniel Chambers
- Juergen Behr
- Mordechai R. Kramer
- Maria De Salvo
- Heidi Bell
- Georgina Viviana Miranda
- Vincent Cottin
- Peter Smith
- Juana Pavie-Gallegos
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Ulsan College (KR)
- The University of Queensland (AU)
- Universitair Ziekenhuis Leuven (BE)
- Rabin Medical Center (IL)
- Inova Fairfax Hospital (US)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- Hospices Civils de Lyon (FR)
- Michigan Medicine (US)
- Prince Charles Hospital (AU)
- German Center for Lung Research (DE)
- United Therapeutics (United States) (US)
- Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (AR)
- Research Center for Integrated Disaster Risk Management (CL)
- Ludwig-Maximilians-Universität München (DE)
- Centro de Estudios Científicos (CL)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1056/nejmoa2512911
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00